Phaseline

Targets › GLP2R

GLP2R (Glucagon-like peptide 2 receptor): drug programs, companies and trials

4 programs from 4 companies in 5 trials: 4 Phase 3, 1 Phase 2; Gastroenterology, Immunology; next expected readout Feb 2027.

This is a receptor for glucagon-like peptide 2. The activity of this receptor is mediated by G proteins which activate adenylyl cyclase. (UniProt, O95838)

Open in Phaseline: the race on GLP2R, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
TakedaTeduglutide
Glucagon-like peptide 2 receptor agonist
GLP2RPhase 3Short Bowel SyndromeFeb 2027
Chongqing Peg-Bio BiopharmPJ009
Glucagon-like peptide-2 (GLP-2) receptor agonist
GLP2RPhase 3Short Bowel SyndromeMar 2027
VectivBioApraglutide
GLP-2 receptor agonist
GLP2RPhase 3Short Bowel Syndrome; Short Bowel Syndrome (SBS)Oct 2027
University Hospital, Gentofte, CopenhagenDapiglutide
Dual GLP-1R/GLP-2R agonist
GLP1R, GLP2RPhase 2Obesity–

Conditions

Short Bowel Syndrome (3) Short Bowel Syndrome (SBS) (1) Obesity (1)

Modalities

protein or peptide (4)

Companies

VectivBio (1) Chongqing Peg-Bio Biopharm (1) University Hospital, Gentofte, Copenhagen (1) Takeda (1)

Related targets

GLP1R (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.